Samsung Bioepis Seeks South Korean Approval for Keytruda Biosimilar SB27
Samsung Bioepis announced on Aug. 10 that it has submitted a marketing authorization application to South Korea's Ministry of Food and Drug Safety...
Search results for "immuno-oncology therapy"
Immuncell-LC Demonstrates Potential in Preventing Liver Cancer Recurrence Following Organ Transplant
A new study suggests that Immuncell-LC, an autologous immune cell therapy, may effectively curb cancer recurrence in liver transplant recipients—a...
Radiation Therapy Shrinks Lymph-Node Tumors in 75% of Advanced Liver Cancer Cases
When hepatocellular carcinoma spreads to the lymph nodes, it is classified as advanced liver cancer, typically...
SK Plasma Launches High-Dose Revolpag 75 mg to Simplify Thrombocytopenia Regimens and Cut Costs
SK Plasma announced on Sept. 1 that it has begun distributing Revolpag Tablets 75 mg in South Korea, expanding its...
Moderna’s Landmark mRNA Cancer Vaccine Phase 3 Success Spotlights Korean Biotech Ties
Positive late-stage clinical results for a personalized messenger RNA cancer vaccine developed by Moderna and Merck are...
Timing of Immune Cell Entry Dictates Anti-Cancer Defense in Hard-to-Treat Brain Tumors
Some immune cells surrounding a tumor actively attack it, while others create conditions that help it survive.
Qurient’s Mocaciclib Opens New Combination Frontiers for Hard-to-Treat Breast Cancer
Qurient announced on June 29 that it presented key clinical data highlighting the mechanistic advantages of its...
From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’
The standard of care in cancer treatment is undergoing a rapid paradigm shift. For decades, the default oncological...
MSD Bets $510M on High-Quality Data to Fuel Post-Keytruda AI Drug Discovery
MSD, which has long dominated the global cancer market with its blockbuster immuno-oncology therapy Keytruda, is...
Celltrion Advances Next-Generation Immuno-Oncology Candidate with Strong Preclinical Results
Celltrion has announced promising preclinical data for its investigational immuno-oncology candidate, CT-P72/ABP-102,...